Pharmacokinetics of intravenous glycyrrhizin after single and multiple doses in patients with chronic hepatitis C infection

Clinical Therapeutics

Volumn 21, Issue 12, 1999, Pages 2080-2090

  Van Rossum, Tekla G J ^a   Vulto, Arnold G ^a   Hop, Wim C J ^a   Schalm, Solko W ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

Glycyrrhizin; Hepatitis C; Pharmacokinetics

Indexed keywords

GLYCYRRHIZIC ACID;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; CHRONIC HEPATITIS; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG ACCUMULATION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG HALF LIFE; FEMALE; HEPATITIS C VIRUS; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; MALE;

EID: 0033392097     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/S0149-2918(00)87239-2     Document Type: Article

References (16)

1. 1. Fujisawa K, Tandon BN. Therapeutic approach to the chronic active liver disease: Summary of a satellite symposium. In: Nishioka K, Suzuki H, Mishiro S, Oda T, eds. Viral Hepatitis and Liver Disease. Tokyo: Springer-Verlag; 1994:662-665.
2. 2. Suzuki H, Ohta Y, Takino T, et al. The therapeutic effects of Stronger Neo Minophagen C for chronic hepatitis. Igaku no Ayumi. 1977;102:562-568.
3. 3. Suzuki H, Ohta Y, Takino T, et al. Effects of glycyrrhizin on biochemical tests in patients with chronic hepatitis. Asian Med J. 1983;26:423-438.
4. 4. Arase Y, Ikeda K, Murashima N, et al. The long term efficacy of glycyrrhizin in chronic hepatitis C patients. Cancer. 1997;79:1494-1500.
5. 5. Akao T, Akao T, Hattori M, et al. Hydrolysis of glycyrrhizin to 18β-glycyrrhetyl monoglucuronide by lysosomal β-d-glucuronidase of animal livers. Biochem Pharmacol. 1991;41:1025-1029.
6. 6. Tanaka N, Yamamura Y, Santa T, et al. Pharmacokinetic profiles of glycyrrhizin in patients with chronic hepatitis. Biopharm Drug Dispos. 1993;14:609-614.
7. 7. Yamamura Y, Tanaka N, Santa T, et al. The relationship between pharmacokinetic behaviour of glycyrrhizin and hepatic function in patients with acute hepatitis and liver cirrhosis. Biopharm Drug Dispos. 1995;16:13-21.
8. 8. Takahashi M, Nakano S, Takeda I, et al. The pharmacokinetics of the glycyrrhizin and glycyrrhetinic acid after intravenous administration of glycyrrhizin for the patients with chronic disease caused by type C hepatitis virus. Nippon Shokakibyo Gakkai Zasshi. 1995;12:1926-1936.
9. 9. Yamamura Y, Kotaki H, Tanaka N, et al. The pharmacokinetics of glycyrrhizin and its restorative effect on hepatic function in patients with chronic hepatitis and in chronically carbon-tetrachloride-intoxicated rats. Biopharm Drug Dispos. 1997;18:717-725.
10. 10. TGJ van Rossum, AC Vulto, WCJ Hop, et al. Intravenous glycyrrhizin for the treatment of chronic hepatitis C: A double-blind, randomized, placebo-controlled trial. J Gastroenterol Hepatol. 1999;14: 1093-1099.
11. 11. Raggi MA, Bugamelli F, Nobile L, et al. HPLC determination of glycyrrhizin and glycyrrhetic acid in biological fluids, after licorice extract administration to humans and rats. Boll Chim Farm. 1994;133: 704-708.
12. 12. Heinzel G, Woloszczak R, Thomann P. Pharmacokinetic and Pharmacodynamic Data Analysis System for the PC. Version 2.0. Stuttgart, Germany: Gustav Fischer Verlag; 1993.
13. 13. Yamamura Y, Kawakami J, Santa T, et al. Pharmacokinetic profile of glycyrrhizin in healthy volunteers by a new high-performance liquid chromatographic method. J Pharm Sci. 1992;81:1042-1046.
14. 14. Krähenbühl S, Hasler F, Krapf R. Analysis and pharmacokinetics of glycyrrhizic acid and glycyrrhetinic acid in humans and experimental animals. Steroids. 1994;59:121-126.
15. 15. Ichikawa T, Ishida S, Sakiya Y, et al. Biliary excretion and enterohepatic cycling of glycyrrhizin in rats. J Pharm Sci. 1986; 75:672-675.
16. 16. Ishida S, Sakiya Y, Ichikawa T, et al. Prediction of glycyrrhizin disposition in rat and man by a physiologically based pharmacokinetic model. Chem Pharm Bull. 1990;38:212-218.